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Abstract: The discovery of the Human Immunodeficiency Virus (HIV) was led by the merge 
of clustered cases of Pneumocystis jirovecii Pneumonia (PCP) in otherwise healthy people in 
the early 80’s.1,2 In the face of sophisticated treatment now available for HIV infection, life 
expectancy approaches normal limits. It has dramatically changed the natural course of HIV from 
a nearly fatal infection to a chronic disease.3–5 However, PCP still remains a relatively common 
presentation of uncontrolled HIV . Despite the knowledge and advances gained in the preven-
tion and management of PCP infection, it continues to have high morbidity and mortality rates. 
Trimethoprim-sulfamethoxazole (TMP-SMZ) remains as the recommended first-line treatment. 
Alternatives include pentamidine, dapsone plus trimethoprim, clindamycin administered with 
primaquine, and atovaquone. For optimal management, clinicians need to be familiar with the 
advantages and disadvantages of the available drugs. The parameters used to classify severity 
of infection are also important, as it is well known that the adjunctive use of steroids in moder-
ate to severe cases have been shown to significantly improve outcome. Evolving management 
practices, such as the successful institution of early antiretroviral therapy, may further enhance 
overall survival rates.
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Introduction
Pneumocystis in humans is caused by P . jirovecii, as opposed to P . carinii, the   latter 
being one of the two Pneumocystis species found only in rats.6 The organism was 
classified as a protozoan nearly 100 years ago.7,8 In 1988 it was identified as a fungus 
based on DNA analysis.9,10 P . jirovecii is a fungus that has maintained its importance 
as a pathogen because of its frequent presentation as pneumonia in patients with T cell 
mediated immunodeficiency.
Examples of those at risk include persons with a primary or hereditary immu-
nodeficiency, persons on antineoplastic therapy, immunosuppressive drugs, gluco-
corticoids, those with hematological malignancies (leukemia, lymphoma, multiple 
myeloma), and of course HIV infection. Three decades into the HIV/AIDS epidemic 
it remains as one of the most prevalent opportunistic infections. It is still a common 
AIDS defining illness leading to the diagnosis of HIV infection and bringing patients 
to medical attention.
P . jirovecii has a worldwide distribution and humans appear to be a reservoir for 
this fungus. The modes of transmission and acquisition are not completely understood. 
It was previously thought that P . jirovecii did not infect the immunologically normal 
host. However, recent studies in immunocompetent animals have shown that P . jirovecii HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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produces a typical pattern of infection, transmission and 
resolution.11 In addition, PCP was traditionally believed to 
arise from reactivation of latent infection. This was probably 
because of the evidence of exposure and likely asymptomatic 
infection early in life and active disease occurring several 
years later. However, no evidence for latency has ever been 
demonstrated. Mouse and rat models of PCP have shown that 
latency does not develop after infection, which suggests that 
PCP results from new infection rather than reactivation of 
latent infection.12 The latter is supported by data showing that 
distinct strains are responsible for each episode in patients 
who develop multiple episodes of PCP.13
P . jirovecii is acquired by inhalation. Once in the alveoli, 
it adheres to type I cells, and the subsequent interaction 
of P. jirovecii with the alveolar epithelium is considered 
critical to the infectious process.14 A significant pulmo-
nary inflammatory response ensues which more potently 
contributes to lung injury than the direct effect of the 
organism during Pneumocystis pneumonia. The importance 
of the immune response was initially demonstrated in an 
experiment in which mice with severe combined immuno-
deficiency were infected with PCP, and following infusion 
with functional lymphocytes, a rapid deterioration and 
even death was seen.15 Subsequent studies showed that the 
restoration of immune function in the presence of PCP, 
resulted in a rapid increase of proinflammatory cytokines, 
chemokines and cellular infiltrate in the lungs of mice, as 
the adopted immune system began to function and clear 
infection.16 In these studies, mice with similar burden of 
infection, but without restoration of immune function, were 
remarkably normal in terms of their cytokine response and 
physiologic parameters. It has been proposed that when a 
balanced CD4+ and CD8+ T-cell response occurs, as in the 
normal host, the infection will lead to mild inflammation 
that will destroy P . jirovecii and with relative preservation 
of lung function. However, when CD8+ T cells initiate the 
inflammatory response in the abscense of sufficient CD4+ T 
cells to control the infection, a hyper-inflammatory response 
follows causing severe lung damage without reducing 
organism burden.17
A detailed discussion of the clinical presentation and 
diagnostic procedures available for PCP is beyond the scope 
of this review, but widely available.18–20 Briefly, the clinical 
presentation can vary, though most patients are usually ill for 
two to three weeks. Progressive dyspnea is characteristic, but 
dry cough, tachycardia, tachypnea, hypoxia, and low-grade 
fever are also common manifestations. Lung auscultation in 
comparison to symptoms is usually unremarkable. Arterial 
blood gas analysis demonstrates an increased alveolar-arterial 
gradient and respiratory alkalosis. Oxygen desaturation of 
$5% with exercise is a reliable and quick test. 21 Early in the 
disease course the chest radiography may be normal, but will 
classically show fine, bilateral, diffuse infiltrates beginning 
in the perihilar regions. Other presentations include cystic 
formation, unilateral infiltrates, cavitary lesions, nodular 
densities, pleural effusion, pneumothorax, and pneumome-
diastinum (Figures 1–6).22 High resolution computer assisted 
tomography (CAT) scans are more sensitive than chest 
radiography in the diagnosis of PCP.23
Definitive diagnosis is based on identification of the 
organism on histopathology. Sputum induction with hyper-
tonic saline has a diagnostic yield ranging from 50 to 90% 
and specificity approaching 100%.24 Fiberoptic bronchoscopy 
with bronchoalveolar lavage has .90% sensitivity and 
100% specificity. Immunofluorescent staining of bronchial 
specimens is the most sensitive and specific diagnostic test 
readily available.25
Polymerase chain reaction testing of induced sputum 
or bronchoalveolar lavage can also identify and quantitate 
Pneumocystis. Several studies have suggested that PCR can 
be a sensitive and specific diagnostic test on these samples, as 
well as oro-pharyngeal washes, but no commercial PCR test 
is broadly available at this time.26 For example some of these 
newer PCR diagnostic tests include assays to amplify the 
human Pneumocystis mithocondrial large subunit rRNA, 
and the internal transcribed spacer region genes. However, 
Figure 1 Chest radiograph showing bilateral diffuse interstitial infiltrates and airspace 
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the availability of an accurate serologic test would be a major 
advance in the diagnosis of PCP. Recent reports describe 
potential candidates such as detection of the serum (1–3) 
beta-D-glucan.27,28
Treatment
Untreated PCP is almost always fatal. In patients without 
HIV infection, response to treatment should begin in 4 to 
5 days. In patients infected with HIV , the treatment response 
  typically takes longer but should occur within the first 
8 days. It is not uncommon to observe clinical deterioration 
in the first 24 hours of the initiation of therapy, especially in 
moderate or severe cases. If no response occurs within the 
expected time, an alternative diagnosis should be sought, 
including concurrent infections;29–31 otherwise, an appropriate 
  alternative regimen should be used.
Figure 2 Case 2, Chest radiograph showing bilateral diffuse interstitial infiltrates 
and airspace opacities of Pneumocystis pneumonia.
Figure 3 One slice from CAT scan of the lungs showing patchy bilateral areas of ground 
glass infiltrates and multiple pneumatoceles taken from a patient with Pneumocystis.
Figure 4 One slice from CAT scan of the lungs showing patchy bilateral areas of ground 
glass infiltrates and multiple pneumatoceles taken from a patient with Pneumocystis.
Figure 5 One slice of CAT scan of the lungs showing widespread emphysematous 
and cystic changes along with multifocal interstitial infiltrates in a severe case of 
Pneumocystis pneumonia.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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The length of treatment is 21 days in HIV-infected patients 
and 14 days in non-HIV infected individuals. It is common 
practice to extend therapy if there is a delay in the resolution 
of signs and symptoms. A longer duration of treatment in HIV-
infected individuals is often needed due to the larger burden 
of organisms and the slower response to therapy.
The dosages of these medications must be adjusted for renal 
or hepatic impairment. Treatment options, including the type 
of medications, need for in-patient care and respiratory support 
will be decided by the treating team and will depend primarily 
on the degree of illness at diagnosis (Table 1). In general, the 
parenteral route is preferred for administering antibiotics to 
patients who present with moderate or severe disease or in those 
with gastrointestinal upset. The recommended and alternative 
schemas of treatment are summarized in Table 2.
Antibiotics
These are the mainstay of treatment for PCP. A summary 
of the dose, contra-indications and common side effects are 
presented in Table 3.
Trimethoprim-sulfamethoxazole  
(TMP-SMX)
Trimethoprim-sulfamethoxazole (TMP-SMX) is the drug 
of choice for pneumocystis. TMP-SMX is made up of two 
antimicrobial agents that act synergistically against a wide 
variety of bacteria. Although trimethoprim has been com-
bined with other sulfonamides, TMP-SMX is by far the most 
widely used. TMP and SMX are individually weak bacteri-
cidal agents, but when given together, they become highly 
bactericidal against many bacteria. Maximum inhibition of 
most susceptible bacteria occurs when the TMP-SMX con-
centration ratio is 1:20. The drug combination is prepared in a 
higher fixed ratio of 1:5; however, peak serum concentrations 
of 1:20 are still achieved by both oral and intravenous therapy 
because of the wider volume of distribution of TMP.
This regimen has been widely recommended as first line 
therapy for the management of HIV-related Pneumocystis 
opportunistic infections.32 It has been shown in numerous 
studies to be more or equally effective as pentamidine which 
was the drug of choice for the treatment of PCP before the 
advent of the HIV/AIDS epidemic. TMP-SMX has the 
advantage of a comparatively favorable toxicity profile and 
has gained wide acceptance due to its long track record and 
easy availability.33–36
A prospective randomized non-crossover trial comparing 
these two regimens, helped to clarify the results of the more 
common complex trials that allowed for frequent changes 
in regimen, due to a lack of response or because of adverse 
effects. This study reported that 86% of patients treated with 
TMP-SMX survived and were without respiratory support at 
completion of treatment compared to 61% in the pentamidine 
group, 95% CI for the difference in response, 5% to 45%; 
P  = 0.03.37
Figure 6 One slice of CAT scan of the lungs showing widespread emphysematous 
and cystic changes along with multifocal interstitial infiltrates in a severe case of 
Pneumocystis pneumonia.
Table 1 Severity of PCP
Degree A-a gradient*
Mild ,35 mmHg
Moderate 35–45 mmHg
Severe** .45 mmHg
*A-a gradient: alveolar-arterial gradient.
**Severe disease also defined by an Oxygen pressure of 70 mmHg taken at room air.
Table 2 PCP treatment regimens
Preferred regimens
•   Trimethoprim (TMP)  
15–20 mg/kg/day + sulfamethoxazole 75–100 mg/kg/day PO or IV for 
21 days in 3 to 4 divided doses.
•   Adjunctive corticosteroids 
In moderate to severe disease should receive corticosteroids  
(prednisone 40 mg PO bid × 5 days, then 40 mg qd ( 5 days, then  
20 mg/day to completion of treatment) starting as early as possible.  
IV methylprednisolone
Alternative regimens
• TMP 15mg/kg/day PO + dapsone 100 mg/day PO × 21 days.
• Pentamidine 3–4 mg/kg/day IV infused over . 60 min × 21 days.
•   Clindamycin 600–900 mg IV q6h–8h or 300–450 mp PO  
q6h + primaquine 15–30 mg/day base PO × 21 days.
• Atovaquone 750 mg suspension PO bid with meal × 21 days.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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The mechanism of action of this combined drug   regimen 
involves the sequential inhibiton of folate biosynthesis by 
the organism. Sulfamethoxazole competitively inhibits 
dihydropteroate synthase (DHPS) which catalyses the con-
densation of p-aminobenzoic acid and 6-hydroxymethyl-7,8-
dihydropterin pyrophosphate to form dihydropteroate.38 
Trimethoprim inhibits microbial dihydrofolate reductase, and 
by this action inhibits purine synthesis and thereby prevents 
deoxyribonucleic acid production. These sequential inhibi-
tors in folic acid synthesis likely results in a synergistic killing 
effect of microbes.39,40
TMP-SMX absorption is not affected by food or other 
medications and bioavailability is approximately 85% for 
both compounds. TMP-SMX is available in oral and paren-
teral forms. Peak serum levels of TMP-SMX after administra-
tion of a double-strength tablet are 1 to 2 microgram/mL and 
25 to 60 microgram/mL, respectively. Peak concentrations 
are attained within 2 to 4 hours with oral therapy and within 
1 to 2 hours with parenteral therapy. The concentrations 
achieved after intravenous administration of TMP-SMX are 
equivalent to two DS tablets and are 3.5 microgram/mL 
and 47.3 microgram/mL respectively. Intravenous therapy 
is preferred when absorption is unreliable. TMP-SMX is 
widely distributed in the body but tissue concentrations 
are generally less than serum concentrations. TMP is more 
lipophilic than SMX (apparent volume of distribution 100 
to 120 L and 12 to 18 L respectively), resulting in ratios of 
1:2 to 1:10 in tissues compared to 1:20 in the extracellular 
fluid. CSF penetration of TMP-SMX is generally good, with 
TMP concentrations ranging from 20% to 60% of serum 
values and SMX concentrations ranging from 12% to 50% 
of serum values. The recommended dose for the treatment 
of PCP is 15 to 20 mg/kg of TMP per day and 75 to 100 mg/
kg of SMX per day, divided in three or four doses.
TMP-SMX is generally well tolerated in non-HIV-
infected patients. Adverse reactions occur in approximately 
6% to 8% of such individuals. In comparison, the adverse 
reaction rate is as high as 25% to 50% in HIV-infected 
patients. In the latter group, treatment limiting toxicities 
occur in one third of cases.41
Reported toxicities include skin reactions (ranging from 
mild rash to anaphylaxis), drug fever, bone marrow suppres-
sion, nausea and vomiting, diarrhea, pancreatitis, nephritis, 
metabolic acidosis, and hyperkalemia. Hyperkalemia is 
due to the blockade of the collecting tubule sodium chan-
nel by trimethoprim (an action similar to that induced by 
the potassium-sparing diuretic amiloride). Hyperkalemia 
is most commonly seen in HIV-infected patients who are 
treated with high doses, but normal doses can also produce 
a modest elevation in the plasma potassium concentration in 
non-HIV-infected subjects.
Nephrotoxicity associated with TMP-SMX is uncommon; 
however, TMP is known to decrease the tubular secretion 
of creatinine. This has led to increases in serum creatinine 
Table 3 Drugs for treatment of PCP
Regimen Dosage Contraindications Common adverse effects
TMP-SMS  
(Bactrim, Septra)
5 mg/kg of TMP every 8 hrs hypersensitivity, megaloblastic anemia  
due to folate deficiency
skin reaction (mild rash to anaphylaxis), drug  
fever, bone marrow suppression, nausea  
and vomiting, diarrhea, pancreatitis, nephritis,  
and hyperkalemia
Dapsone  
(Avlosulfon)
100 mg daily hypersensitivity, G-6-PD  
deficiency
fever, rash, hemolytic anemia, nausea, vomiting, 
methemoglobinemia, hepatitis,  
aplastic anemia
Clindamycin  
(Cleocin)
900 mg IV q 8h hypersensitivity, regional enteritis,  
ulcerative colitis, Hepatic impairment,  
antibiotic associated colitis.
diarrhea, nausea, vomiting, rash,  
clostridium, difficile associated colitis
Atovaquone  
(Mepron)
750 mg PO BID hypersensitivity rash, GI intolerance, diarrhea, headache, fever,  
insomnia
Pentamidine  
Pentam-300
4 mg/kg/d IV/IM hypersensitivity nausea, cardiac arrthytmias, hyperkalemia,  
nephrotoxicity, hypo-hyperglycemia,  
hyper-hypo tension, Hepatic dysfunction,  
leucopenia, thrombocytopenia
Trimetrexate*  
(Neutrexin)
45 mg/m2 IV qd hypersensitivity, severe  
myelosuppression
myelosuppression, increases in serum  
aminotransferase levels, anemia, fever,  
rash/pruritus, and increased alkaline  
phosphatase or serum creatinine levels
Primaquine 15–30 mg PO hypersensitivity, G-6-PD deficiency hemolytic anemia, methemoglobinemia,  
leucopenia, nausea, vomiting, epigastric pain
*No longer available in the US.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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through interference with certain assays that is not reflective 
of a true reduction in glomerular filtration rate.
TMP-SMX desensitization could potentially allow for its 
use in those with hypersensitivity reactions. However, there 
is no established regimen proven to be safe in such patients. 
Mild adverse reactions can be managed with supportive care 
and discontinuation of the drug. Attempts at desensitization 
with increasing doses of bactrim can be done in mild cases but, 
this should never be attempted in those whose adverse event 
involves severe rash with mucosal involvement, or anaphy-
lactic type reactions. With the wide use and success of other 
therapeutic treatments available, clinical circumstances may 
dictate when desensitization procedures are warranted.
Therapeutic failure with TMP-SMX occurs in up to 20% 
of cases and cannot be solely attributable to gene mutations. 
There are no standardized culture systems for P . jirovecii and 
therefore data on drug resistance is unavailable.42 TMP-SMX 
resistance is mainly due to point mutations in dihydropteroate 
synthase, but, the extent of resistance conferred by these 
mutations is unknown without in vitro susceptibility tests.42 
Mutations in the DHPS gene increases with exposure to sulfa 
drugs and in chemoprophylaxis.42 Though the presence of 
these mutations were independently associated with a sig-
nificant increase in 3-month mortality in one study,43 they 
have not been shown to invariably result in treatment failure. 
Additionally, successful outcome with TMP-SMX in these 
instances has been well documented.44
In patients who are allergic to or intolerant of sulfon-
amides, there are several alternatives for mild to moderate 
disease (that is usually with an alveolar-arterial oxygen 
gradient #45 mmHg).
Dapsone
Dapsone is a synthetic sulfone rapidly and almost completely 
absorbed from the gastrointestinal tract. Peak dapsone plasma 
concentrations are reached within 2 to 8 hours after admin-
istration. The mean half-life of elimination is about 20 to 
30 hours. Twenty-four hours after oral ingestion of 100 mg, 
plasma concentrations range from 0.4 to 1.2 µg/ml. A dose 
of 100 mg per day produces steady-state plasma concentra-
tions of free dapsone of 2 to 6 µmol/L.
About 70% of the drug is bound to plasma protein. 
Dapsone is distributed throughout total body water and is 
present in all tissues. However, it tends to be retained in the 
skin, muscle and especially in the liver and kidney. Traces of 
the drug are present in these organs up to 3 weeks after cessa-
tion of therapy. Following absorption from the gastrointestinal 
tract, dapsone is transported through the portal circulation 
to the liver, where it is metabolized by both N-acetylation 
and N-hydroxylation. Dapsone toxicity, in particular meth-
emoglobin formation, is generally thought to be initiated by 
N-oxidation, resulting in the formation of a hydroxylamine 
metabolite by cytochrome P450.
Dapsone acts against bacteria and protozoa in the same 
way as sulphonamides, by inhibiting the synthesis of dihy-
drofolic acid through competition with para-amino-benzoate 
for the active site of dihydropteroate synthetase. Its efficacy 
is similar to TMP-SMX in mild to moderately severe disease 
with less toxicity.45 Dapsone 100 mg daily plus trimethoprim 
15 mg/kg daily is given by mouth in 3 divided doses.
Dapsone therapy may cause a variety of adverse effects, 
which may be categorized as pharmacologic, dose-dependent, 
allergic, or idiosyncratic reactions. The most frequent and 
well-documented pharmacologic reactions are the hemato-
logical side-effects, such as methemoglobinemia, hemolysis 
(in patients who have glucose 6 phosphate dehydrogenase 
(G6PD) deficiency) and anemia. Methemoglobinemia occurs 
to some extent in all patients receiving dapsone and becomes 
less pronounced as treatment is continued due to an adaptive 
increase in the activity of nicotinamide adenine dinucleotide 
(NADH) dependent reductase in the erythrocytes. Meth-
emoglobin levels of below 20% are not usually associated 
with symptoms. Dyspnea, nausea and tachycardia usually 
occur at levels of 30% or above, while lethargy, stupor and 
deteriorating consciousness occur as methemoglobin levels 
approach 55%. Levels of 70% are usually fatal. Once meth-
emoglobinemia is suspected, evaluation with a complete 
blood count to identify anemia or thrombocytopenia, a blood 
smear for Heinz body formation, G6PD assay, arterial blood 
gas and methemoglobin level should be performed to confirm 
the diagnosis.
Case reports of dapsone-induced methemoglobinemia in 
the literature describe the improvement of mild symptoms 
with discontinuation of therapy and supportive measures.46 
While more symptomatic presentations are treated with meth-
ylene blue and activated charcoal to prevent further gastroin-
testinal absorption. Methylene blue acts as a co-factor for the 
alternative pathway of the nicotinamide adenine dinucleotide 
phosphate (NADPH) system, to convert methaemoglobin 
to haemoglobin.47 However, methylene blue should not be 
administered in the presence of G6PD deficiency, where low 
levels of NADPH exist making it ineffective. In this situation 
methylene blue may induce hemolytic anemia, and blood 
transfusions are likely to be more useful here, and in cases 
refractory to treatment with methylene blue.48 Treatment of 
PCP should resume with alternative options for PCP.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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Other side effects include fever, nausea, vomiting, 
peripheral motor weakness, dose-unrelated granulocytopenia, 
aplastic anemia, and cutaneous reactions such as the sulfone 
syndrome.
Clindamycin
Clindamycin is another comparable alternative to TMP-SMX 
in terms of therapeutic success and safety.49 The dose is 
300–450 mg orally four times a day (or 600–900 mg IV every 
6 to 8 hours) plus primaquine 15–30 mg of base daily. The 
mechanism of action of both clindamycin and primaquine 
against Pneumocystis is unknown. The most common adverse 
reactions with this regimen include skin rash, gastrointestinal 
complaints, and fever. Primaquine may also cause hemolysis 
in patients with G6PD deficiency.
Atovaquone
Atovaquone is hydroxy-1,4-naphthoquinone, an analog of 
ubiquinone, that was initially developed as an antimalarial 
agent. It also has activity against P. jirovecii but is less 
effective than the above regimens.The mechanism of action 
of atovaquone in infections caused by P . jirovecii has not 
been fully elucidated. However, among Plasmodium species 
the site of action appears to be the cytochrome bc1 complex 
(Complex III). Several metabolic enzymes are linked to 
the mitochondrial electron transport chain via ubiquinone. 
Inhibition of electron transport by atovaquone will result in 
indirect inhibition of these enzymes. The ultimate metabolic 
effects of such blockade may include inhibition of nucleic 
acid and ATP synthesis.
Atovaquone is a highly lipophilic compound with low 
aqueous solubility. The bioavailability of atovaquone is 
highly dependent on formulation and diet. In suspension it 
provides an approximately 2-fold increase in bioavailability 
in the fasting or fed state compared to the previously mar-
keted tablet formulation. Plasma atovaquone concentrations 
do not increase proportionally with dose.
A randomized, double-blind, controlled trial showed simi-
lar rates of successful therapy when comparing atovaquone to 
TMP-SMX in patients with mild to moderate disease (defined 
in the study protocol as an alveolar-arterial oxygen gradient 
#45 mmHg and partial pressure of oxygen $60 mmHg mea-
sured on room air) and with less adverse events. However, 
significantly higher 4-week mortality rates and significantly 
higher rates of no response to therapy were noted in the atova-
quone group.50 Conditions affecting absorption and thereby 
decreasing the bioavailability of atovaquone were associated 
with poorer therapeutic outcomes.50 Efficacy has also been 
shown to be comparable to pentamidine in mild to moderate 
disease.51 The usual dose is in suspension, 750 mg orally twice 
daily, taken with food to increase its absorption.
Adverse reactions include skin rash, fever, gastrointestinal 
symptoms, and abnormal liver function tests. Mutations in 
the cytochrome b gene have been shown to confer resistance 
to atovaquone.
Pentamidine isethionate
Pentamidine isethionate is effective therapy for Gambian 
trypanosomiasis, antimony-resistant leishmaniasis, and 
P . jirovecii pneumonia. Between 1967 and 1984 its use 
was restricted to treating infections due to Trypanosoma 
gambiense and Pneumocystis jirovecii. It then became more 
commonly used for treatment of PCP among immunocom-
promised patients before the HIV/AIDS epidemic. The 
mechanism of action is unclear and may differ for different 
organisms. Trypanosomes actively transport pentamidine 
intracellularly, where it may then interfere with DNA biosyn-
thesis. With Pneumocystis pneumonia, pentamidine appears 
to kill nonreplicating organisms.
There are many studies showing similar efficacy of pent-
amidine to TMP-SMX, but the former is not favored because 
of known toxicities and its availability only as an intravenous 
preparation.52–54 Pentamidine is given parentally at 4 mg/kg 
once daily and is generally regarded as second-line therapy 
in severe disease with consideration of its side effect profile. 
The aerosol route is recommended only for prophylaxis but 
not for treatment of PCP.
Side effects occur in up to 50% of patients receiving pent-
amidine. These reactions have conveniently been categorized 
as immediate, local, and systemic and have also included 
deaths. Immediate reactions include hypotension in up to 10%, 
tachycardia, nausea and/or vomiting, facial flushing, pruritis, 
unpleasant taste, hallucinations, and syncope. Local reactions 
of moderate to severe pain at the injection site and less fre-
quently, sterile abscesses and tissue necrosis can occur when 
given intramuscularly. Urticarial rash, phlebitis and venous 
thrombosis complicate intravenous administration. Systemic 
reactions include renal toxicity, electrolyte abnormalities, 
hypo- and hyperglycemias, cardiac arrhythmias, elevated 
transaminases and bronchospasm with inhaled treatment.
Trimetrexate
Trimetrexate is a folinic acid analog structurally related to 
methotrexate, whose primary mechanism of action is believed 
to be inhibition of dihydrofolate reductase. This reduces the 
production of DNA and RNA precursors and leads to cell death. HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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Trimetrexate is lipophilic and can passively diffuse across cell 
membranes including those of Pneumocystis jiroveciii and its 
mammalian host. To minimise toxicity, trimetrexate must be 
given with calcium folinate (leucovorin calcium). Leucovorin 
acts as a reduced folate coenzyme, which is transported into, 
and protects mammalian host cells, but does not protect target 
organisms. The recommended dose is 45 mg/m2 once daily, by 
the intravenous route. Leucovorin is administered every 6 hours 
at a dose of 20 mg/m2 and should be continued for 72 hours 
following the last dose of trimetrexate.
The most common adverse effect associated with trime-
trexate is myelosuppression (neutropenia and thrombocy-
topenia) that is generally reversible upon dosage reduction 
or discontinuation. Other adverse effects include increases in 
serum aminotransferase, alkaline phosphatase and/or serum 
creatinine levels, anemia, fever, rash and pruritus. Trime-
trexate is an alternative option for patients with moderate to 
severe PCP who have not responded to or are intolerant of 
first-line therapy. However, it is no longer available in the US 
since its production was discontinued in March 2007.
Adjunctive therapy
In addition to antibiotics, steroids are recommended as 
adjunctive therapy for moderate to severe PCP (defined 
as an arterial oxygen pressure of less than 70 mmHg or an 
alveolar-arterial gradient greater than 35 mmHg). Ideally, 
steroids should be given prior to the first dose of any antibi-
otic or no later than the first 72 hours after the initiation of 
therapy.55,56 The usual “steroid regimen” consists of predni-
sone 40 mg orally twice daily for the first five days, 40 mg 
orally daily for another five days, followed by 20 mg orally 
once daily for an additional 11 days. Methylprednisolone at 
75% of the respective prednisolone dose should be adminis-
tered if intravenous therapy is necessary. During the first days 
of therapy adjunctive steroids improve, most importantly, 
survival, decrease episodes of respiratory decompensation 
and decrease the need for mechanical ventilation. Steroids 
likely blunt the inflammatory response (that includes the 
production of cytokines and other inflammatory markers and 
cells) to dying organisms that results in lung tissue damage 
during the early course of therapy.57
Future directions and challenges
Caspofungin
Caspofungin is an echinocandin and inhibits fungal beta-1,3-
glucan synthesis, a main component of the cell wall. It is 
known to have activity against Candida and Aspergillus 
species. There is data on its efficacy in cystic forms of PCP 
in murine models.58 Case reports have described its clinical 
success when used in combination with TMP-SMX in   treating 
PCP in immunocompromised hosts.59–61 Though these reports 
seem promising, clinical trials are needed to support these 
findings before Caspofungin can be   recommended in the 
treatment of PCP.
Antiretroviral therapy
Early in the AIDS epidemic, patients with severe PCP and 
respiratory failure had such high mortality rates that mechani-
cal ventilation and intensive care were not encouraged. There 
has been a gradual improvement in survival over the last two 
decades with the adjunctive use of steroids in therapy and 
improved intensive care management of these patients.62,63 
This trend can be further enhanced with the early initiation of 
combination antiretroviral therapy (cART).64 The optimal tim-
ing for initiation of cART has been a subject of debate. There 
are well-deserved concerns regarding cART and the possibil-
ity of the immune reconstitution and inflammatory response 
syndrome (IRIS), with paradoxical worsening of PCP and 
other opportunistic infections (OI). One review of 65 cases of 
PCP describes an acute worsening of respiratory symptoms 
in 3 patients after the early introduction of cART. However, 
they did not report any deaths among these 3 cases.65
The first study looking at the use of cART in patients 
presenting with severe PCP found cART to be an indepen-
dent predictor of decreased mortality. The mortality among 
patients not receiving cART was 63% in contrast to a signifi-
cantly lower 25% mortality among patients receiving cART 
prior to or during hospitalization.66 This initial study set the 
stage for a more recent multicentered randomized trial where 
early cART was started within 14 days of diagnosis of an OI 
versus deferred therapy where cART was started after treat-
ment of the OI was completed; usually $4 weeks into the 
study. It was shown that AIDS progression and death were 
significantly reduced in the early treatment group, especially 
within the first 6 months of the study. Additionally, for the 
OIs included within this study of which 63% where due to 
PCP, the incidence of IRIS was surprisingly low at 7%. The 
improved outcome seen with early cART substantiates its 
consideration in clinical practice along with the fact that 
patients can usually be supported through an episode of 
IRIS if it ocurrs.67
However, there are some reservations among physicians 
to the use of early cART. These include non-compliance, 
loss of follow up post-discharge, drug interactions and the 
potential for drug toxicities. In regard to critically ill patients 
especially on hemodynamic supportive therapy, the safety of 
cART has not been extensively studied. Limitations of poor 
absorption of orally administered medications, by which HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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most   antiretrovirals are given, may be erratic, predisposing to 
resistance and decreased efficacy. Frequent changes in renal 
and hepatic function can make it difficult to accurately dose 
medications and the detection of drug adverse effects may 
be delayed in obtunded patients.68 Moreover, to facilitate a 
smooth transition to out-patient care, access to medications 
and providers should be in place prior to discharge from 
hospital.
Challenges in the management  
of opportunistic infections
There is a changing approach to the treatment of oppor-
tunistic infections, with the accumulating evidence of the 
early initiation of cART improving morbidity and mortality. 
Additional clinical trials showing this benefit are needed to 
develop guidelines on what could become the standard of 
care. A better understanding of the pathogenesis of IRIS and 
ongoing studies to help predict those that are susceptible may 
quell the concerns surrounding early cART, provide more 
answers and may even lead to improved outcome.
Prevention
Primary prophylaxis
Studies have shown that a CD4 count less than 200 cells/mm3 
(or CD4 percentage less than 14) in an HIV-infected patient 
markedly increases the risk for PCP, and is an indication to 
start primary prophylaxis. One prospective observational 
study that supports this recommendation, found 88.9% of 
3101 initial episodes of PCP among an HIV-infected popu-
lation, had a CD4 count less than 200.69 Although PCP is 
known to occur at higher CD4 counts, the risk is lower, 
and probably outweighs the potential for a large number of 
adverse events with prophylactic therapy. Oropharyngeal 
candidiasis is another indicator for prophylactic therapy, 
regardless of the CD4 count. Other non-HIV infected 
patients at risk for PCP include those with hematologic 
malignancies, solid tumors, inflammatory disorders, as well 
as bone marrow and solid organ transplant recipients.70 For 
these groups of patients, guidelines on prophylaxis have 
not been established, but they are considered to be at simi-
lar risk as patients with advanced HIV infection. Patients 
who develop severe PCP while on prophylaxis have a poor 
outcome and this may be due to acquired co-trimoxazole 
resistance.71,72
TMP-SMX is very effective in preventing PCP opportu-
nistic infections and is the preferred prophylactic regimen. 
Aerosolized pentamidine is not as effective as bactrim for 
primary or secondary PCP prophylaxis.73,74 However, it is 
an alternative option for those unable to tolerate TMP-SMZ 
as stated in the most recent guidelines on the prevention of 
opportunistic infections in HIV-infected adults and adoles-
cents.75 Although aerosolized pentamidine has higher failure 
rates compared to bactrim, it has been shown that compared 
to those at risk and not receiving prophylactic therapy, it 
significantly reduces the incidence of primary episodes of 
PCP with reasonable tolerance of the inhaled drug.76
Atovaquone is another alternative to bactrim for prophy-
laxis. A study comparing atovaquone to aerosolized pentami-
dine showed no statistically significant differences between 
these two drugs with regard to incidence of PCP, death, or the 
combined end point of PCP and death.77 Atovaquone has also 
been shown to have similar efficacy compared to dapsone, 
the latter being the second most widely used option for PCP 
prophylaxis. In a large randomized study among patients with 
intolerance to bactrim, the rates of PCP pneumonia, survival, 
and tolerance were similar in the atovaquone and dapsone 
groups.78 The recommended regimens for prophylaxis are 
listed in Table 4.
Primary prophylaxis may be discontinued once immune 
reconstitution with CD4 counts $200 cells/mm3 for at least 
three months occurs with antiretroviral therapy. Nevertheless, 
it may be possible, to safely discontinue primary prophylaxis 
for those patients who have failed to show an increase in the 
CD4+ T-cell count above the threshold of 200 cells/mm3, 
despite being well controlled on cART, with HIV viral loads 
,50 copies/ml for at least 3 months. It should be noted 
that the latter is not recommended, but, there is evidence 
that immune recovery may occur with suppression of HIV 
alone, even though it is typically thought to be indicated by 
an increase in the CD4+ T-cell count.79 The decreased toxicity 
and cost with improved adherence to cART would together 
be of considerable benefit for such patients.
On the other hand, HIV viral loads have not been used 
to assess the risk for developing PCP and have not been 
included in guidelines to help determine when to initiate or 
discontinue prophylaxis.
Prophylactic therapy should be re-introduced if the CD4 
count decreases to less than 200 cells/mm3.
Table 4 Recommended regimens for PCP prophylaxis
TMP-SMZ one Double Strength tablet once daily or three times a week, or 
once daily single-strength tablet by mouth (preferred)
Dapsone 100 mg daily
Dapsone 50 mg daily with pyrimethamine 50 mg plus folinic acid 25 mg  
once weekly
Atovaquone suspension 750 mg twice daily
Aerosolized pentamidine 300 mg every four weeks administered  
via Respirgard II® nebulizerHIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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Secondary prophylaxis
Patients with a history of PCP should have lifelong chemo-
prophylaxis, with any of the above mentioned regimens, if 
immune reconstitution cannot be achieved. If the CD4 count 
is maintained above 200 cells/mm3 for at least three months 
in response to cART, then it may be discontinued. Secondary 
prophylaxis should be restarted if the CD4 count declines to 
less than 200 cells/mm3 or if PCP recurred with CD4 counts 
above 200 cells/mm3.80
Conclusion
PCP is today still one of the most common and most deadly 
opportunistic infections in patients with Human Immuno-
deficiency Virus. It is also becoming more prevalent among 
non-HIV infected individuals as the number of patients under-
going chemotherapy and immunosuppresion after transplant 
is growing. Clinicians must be familiar with its presentation 
and management because mild cases are sometimes difficult 
to diagnose. On the other hand, some severe cases can prove 
fatal despite full supportive intensive care with mechanical 
ventilation. Currently, the most effective medication for its 
prevention and treatment is trimethoprim-sulfamethoxazole 
but other alternative medications are also available.
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